New scanner aims to cut repeat breast cancer surgeries
NCT ID NCT07352930
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This trial tests a new device called the EndoSCell Scanner, which uses fluorescence imaging to help surgeons see if any cancer cells remain after removing a breast tumor. About 172 women with breast cancer will have their surgical cavity scanned during surgery. If the scanner detects possible leftover cancer, the surgeon can remove more tissue right away. The goal is to lower the chance of needing a second surgery to clear remaining cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EndoSCell Scanner (ES Scanner) device
- What this could lead to
- If successful, this device could help surgeons remove all cancer cells during breast-conserving surgery, reducing the need for a second operation.
- What could go wrong
- This is an early-stage trial with only 172 participants, so results may not apply to all patients. The device's accuracy in detecting cancer cells is still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 172 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Pathologically confirmed diagnosis of primary invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component. Acceptable diagnostic methods include core needle biopsy or fine-needle aspiration biopsy. 2. Female, age ≥ 18 years. 3. Scheduled to undergo breast-conserving surgery for the malignant breast lesion. 4. Willing and able to comply with the study procedures and follow-up. 5. Has provided written informed consent. 6. No other uncontrolled serious medical conditions aside from the cancer diagnosis (see Exclusion Criteria for details). 7. Adequate organ and bone marrow function, defined as: * White blood cell count \> 3,000/μL * Platelet count \> 75,000/μL * Total bilirubin ≤ institutional upper limit of normal (ULN) * AST (SGOT) / ALT (SGPT) \< 2.5 × institutional ULN * Serum creatinine ≤ 1.5 mg/dL, OR creatinine clearance \> 60 mL/min/1.73 m² (for participants with serum creatinine levels above institutional ULN) 8. ECOG performance status of 0 or 1. Exclusion Criteria: 1. Pregnancy or lactation. 2. Suspected pregnancy. 3. Prior injection of ICG or other fluorescent dyes for sentinel lymph node mapping on the day of surgery, before the planned lumpectomy cavity scan with the study device. 4. Unresolved adverse events from previous medications or diagnostic agents. 5. Uncontrolled hypertension, defined as persistent systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg. Patients with known hypertension must be stable on medication within these limits. 6. History of allergy to any oral or intravenous contrast agent. 7. Uncontrolled comorbidities, including but not limited to: * Active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Hospitalization for COPD or asthma within the past 12 months * Psychiatric illness/social situations that would limit compliance with study requirements. 8. Any condition where, in the investigator's judgment, participation would not be in the best interest of the participant. 9. Planned re-excision lumpectomy due to positive margins from a prior surgery performed before enrollment. 10. Prior surgical history in the ipsilateral breast, including breast cancer surgery, mastectomy, breast reconstruction, or implant placement.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast conserving surgery are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Microscope aims to spare breast cancer patients a second surgery
- Which technique best finds hidden breast tumors? large study puts localization methods to the test
- Donor nerve grafts put to the test for restoring feeling after mastectomy
- Can a Hormone-Binding protein predict breast cancer risk? trial tests tamoxifen and fasting
- Can a new imaging agent light up breast cancer tumors?
- Can a radioactive tracer pinpoint Cancer's first stop?